Literature DB >> 16840746

The bacteriology of pleural infection by genetic and standard methods and its mortality significance.

Nick A Maskell1, Sarah Batt, Emma L Hedley, Christopher W H Davies, Stephen H Gillespie, Robert J O Davies.   

Abstract

BACKGROUND: Antibiotic choices for pleural infection are uncertain as its bacteriology is poorly described.
METHODS: Pleural fluid from 434 pleural infections underwent standard culture and a screen for bacteria by amplification and sequencing of bacterial 16S ribosomal RNA gene.
RESULTS: Approximately 50% of community-acquired infections were streptococcal, and 20% included anaerobic bacteria. Approximately 60% of hospital-acquired infections included bacteria frequently resistant to antibiotics (methicillin-resistant Staphylococcus aureus, 25%; Enterobacteriaceae, 18%; Pseudomonas spp., 5%, enterococci, 12%). Mortality was increased in hospital-acquired infection (hospital, 17/36 [47%]; community, 53/304 [17%]; relative risk, 4.24; 95% confidence interval, 2.07-8.69; p < 0.00001; chi(2), 1 df = 17.47) and in gram-negative (10/22 [45%]), S. aureus (15/34 [44%]), or mixed aerobic infections (13/28 [46%]), compared with streptococcal infection (23/137 [17%]) and infection including anaerobic bacteria (10/49 [20%]; p < 0.00001, chi(2), 4 df = 23.35).
CONCLUSION: Pleural infection differs bacteriologically from pneumonia and requires different treatment. Antibiotics for community-acquired infection should treat aerobic and anaerobic bacteria. Hospital-acquired, gram-negative S. aureus and mixed aerobic infections have a high mortality rate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16840746     DOI: 10.1164/rccm.200601-074OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  61 in total

Review 1.  Pleural infection.

Authors:  John M Wrightson; Nick A Maskell
Journal:  Clin Med (Lond)       Date:  2012-02       Impact factor: 2.659

2.  Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose.

Authors:  Najib M Rahman; Eleanor K Mishra; Helen E Davies; Robert J O Davies; Y C Gary Lee
Journal:  Am J Respir Crit Care Med       Date:  2008-06-12       Impact factor: 21.405

3.  Lung biopsies for interstitial lung disease: the limits of the traditional methods of microbiological identification.

Authors:  Xavier Benoit D'Journo
Journal:  Eur J Cardiothorac Surg       Date:  2012-01       Impact factor: 4.191

4.  Therapeutic strategy for acute pleural empyema: comparison between retrospective study and prospective study.

Authors:  Hitoshi Suzuki; Shin Shomura; Yasuhiro Sawada; Akira Shimamoto; Chiaki Kondo; Motoshi Takao; Hideto Shimpo
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-05-03

5.  The ongoing struggle with empyema management: is surgery really the answer?

Authors:  Eihab O Bedawi; Lonny Yarmus; Najib M Rahman
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

6.  Risk Stratification in Patients with Complicated Parapneumonic Effusions and Empyema Using the RAPID Score.

Authors:  Sunkaru Touray; Rahul N Sood; Daniel Lindstrom; Jonathan Holdorf; Sumera Ahmad; Daniel B Knox; Andres F Sosa
Journal:  Lung       Date:  2018-08-11       Impact factor: 2.584

7.  Emergence of parapneumonic empyema in the USA.

Authors:  Carlos G Grijalva; Yuwei Zhu; J Pekka Nuorti; Marie R Griffin
Journal:  Thorax       Date:  2011-05-26       Impact factor: 9.139

Review 8.  Pneumonia and empyema: causal, casual or unknown.

Authors:  Lindsay McCauley; Nathan Dean
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

9.  Pleural infection-current diagnosis and management.

Authors:  Andrew Rosenstengel
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

10.  Mannose-binding lectin genotypes: lack of association with susceptibility to thoracic empyema.

Authors:  Stephen J Chapman; Fredrik O Vannberg; Chiea C Khor; Anna Rautanen; Nicholas A Maskell; Christopher W H Davies; Catrin E Moore; Nicholas P Day; Derrick W Crook; Robert J O Davies; Adrian V S Hill
Journal:  BMC Med Genet       Date:  2010-01-15       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.